NMD activation has been considered as a therapy, e.g., for amyotrophic lateral sclerosis (ALS) to degrade PTC-containing transcripts and to prevent the production of harmful protein forms (Jaffrey and Wilkinson, 2018). The gene discussed is PLA1A; the disease is amyotrophic lateral sclerosis.